Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mind Medicine (MindMed) Inc. - Common Shares
(NQ:
MNMD
)
8.280
-0.230 (-2.70%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 19, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mind Medicine (MindMed) Inc. - Common Shares
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
Mind Medicine Stock Is Not a Trip To Take Just Yet
May 27, 2021
Psychedelic drugs may eventually be a big market. However, investors in MNMD stock may be getting in a little too early.
Via
InvestorPlace
Topics
Cannabis
Law Enforcement
Exposures
Cannabis
Legal
MindMed Collaborates with Nextage Therapeutics for Brain Targeting Liposome System
May 24, 2021
MindMed (NASDAQ: MNMD) and Israel-listed Nextage Therapeutics have entered into an exclusive collaborative development program to optimize the delivery of...
Via
Benzinga
Psyched: MindMed To Begin Mescaline Trials and Deepak Chopra Partnership, Seelos And Cybin Advance Clinical Research
May 24, 2021
MindMed’s News Spree: Mescaline Trials, Chopra Foundation Partnership and LSD Research MindMed (NASDAQ:
Via
Benzinga
Cannabis Movers & Shakers: The Parent Company, MindMed, Australis, Flourish Software
May 20, 2021
The Parent Company Welcomes Desiree Perez To Its Board TPCO Holding Corp. (OTCQX:
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
The Jury’s Still Out on Psychedelics Play MindMed Stock
May 20, 2021
Selling off after its NASDAQ uplisting, it's hard to tell whether MNMD stock will soar higher following recent positive developments.
Via
InvestorPlace
MindMed To Conduct The First Modern Research On Mescaline In Switzerland
May 20, 2021
MindMed (NASDAQ: MNMD) (NE...
Via
Benzinga
Psychedelic Drug Developer Sets Sights On This Age-Old Hallucinogen
May 20, 2021
MindMed stock fell after it said a Swiss ethics committee cleared it to begin a study on the effects of the hallucinogen mescaline.
Via
Investor's Business Daily
22 Stocks Moving in Wednesday's Pre-Market Session
May 19, 2021
Gainers Advaxis, Inc. (NASDAQ: ADXS) shares rose 29.6% to $0.6289 in pre-market trading after jumping over 14% on Tuesday. LightPath Technologies, Inc. (NASDAQ: LPTH) rose 16.3%...
Via
Benzinga
Strong Cash Balance Should Provide a Foundation for MindMed Stock
May 18, 2021
Now that it has joined the Nasdaq Exchange, MNMD stock will have its ups and downs but firm financials should instill shareholder confidence.
Via
InvestorPlace
MNMD Stock: The Big News That Has MindMed Investors Psyched Today
May 17, 2021
MindMed (MNMD) stock is getting a boost on Monday following news from the FDA that allows the company to continue development.
Via
InvestorPlace
Exposures
Product Safety
MindMed Stock Moves Higher After Finalizing Generalized Anxiety Disorder As Initial Indication For LSD Trial
May 17, 2021
After receiving Type C Meeting Responses from the FDA, MindMed (NASDAQ: MNMD) has selected Generalized Anxiety Disorder as an initial indication for its Project Lucy,...
Via
Benzinga
Exposures
Product Safety
Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public
May 17, 2021
Two of the most prominent companies in the psychedelics space released their financials for the first quarter of 2021. Compass Pa...
Via
Benzinga
Exposures
Product Safety
EXCLUSIVE: MindMed CEO Talks Mission To 'Discover, Develop And Deploy' Psychedelics
May 13, 2021
Mind Medicine Inc (NASDAQ: MNMD) was started to address mental wellness, CEO and co-founder J.R. Rahn told Benzinga's Global Small Cap Conference Thursday. MindMed...
Via
Benzinga
Benzinga Global Small Cap Conference: How Do Investors Pick Winners In The Psychedelics Space?
May 13, 2021
Simeon Schnapper, a managing partner at JLS Fund, took 30 minutes from his busy schedule to share his insights into what makes a w...
Via
Benzinga
Video: Psychedelic Stocks With JLS Fund's Simeon Schnapper & MindMed's JR Rahn
May 13, 2021
During the Benzinga Global Small-Cap Conference on Thursday morning, psychedelics executives discussed the markets and companies' prospects.
Via
Benzinga
Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week
May 11, 2021
Welcome to the Cannabis Countdo...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Psyched: Groundbreaking Phase 3 Results On MDMA, Small Pharma, Wesana Go Public, Gilgamesh Raises $27M
May 10, 2021
Last week, the psychedelics space was moved by results from the world’s first Phase 3 clinical study of a scheduled psychedelic compound...
Via
Benzinga
Video: The Psychedelics Market With Entheon Biomedical, MagicMed, Natan Ponieman
May 06, 2021
Benzinga’s Cannabis Hour is a live show for cannabis investors. On Thursday’s show, hosts Patrick&...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Why Smaller Psychedelics Companies Should Start Catching Up To The Sector Leaders
May 05, 2021
Concentration of ownership in psychedelic drug stocks has reached a new extreme. We explain how and why we don't see this trend as being sustainable.
Via
Talk Markets
The Next Psychedelic Stock To Uplist On The Nasdaq?
May 04, 2021
As MindMed Inc makes its long-awaited move to the Nasdaq, the obvious question is: who's next?
Via
Talk Markets
When Will The Selling Pressure In These 2 Hot Stocks End?
May 04, 2021
On April 29, shares of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) hit a wall of resistance at the $4.30 level. Since then, they have been in a freefall. There’s a good...
Via
Benzinga
Mind Medicine Stock Is Soaring After Its NASDAQ Debut. What's Next?
May 04, 2021
Diversification may be a prudent step.
Via
The Motley Fool
12 Health Care Stocks Moving In Monday's Intraday Session
May 03, 2021
Gainers Precipio (NASDAQ:PRPO) stock moved upwards by 111.42% to $3.85 during Monday's regular session. The current volume of 113.0 million shares is 18552.84% of...
Via
Benzinga
Is It Time to Sell These 3 Stocks?
May 03, 2021
It may be time to sell GameStop Corp. (NYSE: GME), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), and Archer-Daniels-Midland Company (NYSE: ADM) and the reasons why will...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 03, 2021
Gainers BioVie (NASDAQ:BIVI) shares increased by 12.96% to $19.78 during Monday's pre-market session. The company's market cap stands at $275.2 million. Ocugen (...
Via
Benzinga
Fintech Focus Roundup For May 2, 2021
May 02, 2021
Apex Fintech Solutions Announces Blow-Out Earnings Ahead Of NYSE Listing What Happened: Blank-check company Northern Star Investment Corporation II announced that Apex...
Via
Benzinga
Exposures
Glyphosate
The 'Boiler Room' Stock Pitch Recap: MindMed, Ford, Generac, Microchip And More
April 30, 2021
Every Friday, at 3 p.m. ET, Ritholtz Wealth Management CEO Josh Brown and Benzinga CEO ...
Via
Benzinga
MindMed Stock Hits A Wall Of Resistance
April 30, 2021
Shares of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) have hit a wall of resistance at the $4.30 level. This has put a top on the stock. Resistance is a large concentration of...
Via
Benzinga
MindMed's Nasdaq Listing Enables Institutions Diversified Access To A New Age Of Medicine
April 30, 2021
Mind Medicine (MindMed) Inc (NASDAQ:MNMD) (NEO: MMED), a l...
Via
Benzinga
60 Biggest Movers From Yesterday
April 29, 2021
Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) shares gained 75.6% to settle at $43.73 on Wednesday. The company recently said it paid $1 million towards acquisition of...
Via
Benzinga
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.